Merck & Co.
1891
FOUNDED
PUBLIC
STATUS
65K-70K
EMPLOYEES
MRK
STOCK SYMBOL
54
INVESTMENTS
$86.91
SHARE PRICE
(As of Wednesday Closing)
Description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiovascular disease, asthma, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, close to 40% of the company's sales are generated in the United States.
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Stock Exchange
NYS
Primary Office
- 2000 Galloping Hill Road
- Kenilworth, NJ 07033
- United States
+1 (908) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Merck & Co.’s full profile, request a free trial.
Merck & Co. Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $66.10 - $87.25 | $223B | $85.65 | $3.60 | 10.1M | 2.57B |
Merck & Co. Financials Summary
|
In Thousands,
USD |
TTM
30-Jun-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | 233,112,934 | 212,235,768 | 169,355,061 | 174,601,686 |
| Revenue | 44,367,000 | 42,294,000 | 40,122,000 | 39,807,000 |
| EBITDA | 16,051,000 | 13,649,000 | 11,566,000 | 10,495,000 |
| Net Income | 9,362,000 | 6,220,000 | 2,394,000 | 3,920,000 |
| Total Assets | 83,965,000 | 82,637,000 | 87,872,000 | 95,377,000 |
| Total Debt | 26,587,000 | 25,114,000 | 24,410,000 | 24,842,000 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Merck & Co. Competitors (69)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Bristol-Myers Squibb | Corporation | New York, NY | 00000 | 00000 | 000000000 | 00000 |
| 000 00000 | Corporation | Indianapolis, IN | 00000 | 0000 | ||
| 0000000 | Pending Transaction (PE) | Summit, NJ | 0000 | 000.00 | 000000&0 | 000.00 |
| 000000 00000000 | Formerly VC-backed | Foster City, CA | 00000 | 00.000 | 000000000 | 00.000 |
| 000000000000000 | Corporation | Brentford, United Kingdom | 000000 | 00000000000 |
Merck & Co. Investments & Acquisitions (54)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000 000000000000 | 01-Jun-2019 | 000000000000000000 | 00000 | Biotechnology | 0000 00 00.0 |
| 0000000 0000000000 | 21-May-2019 | 000000000000000000 | 00.000 | Pharmaceuticals | 0000000 0000000 00 |
| 00000000 | 01-Apr-2019 | 000000000000000000 | 00.00 | Electronic Equipment and Instruments | 0000000 0000000 00 |
| 000000 000000 | 21-Feb-2019 | 000000000000000000 | 00000 | Biotechnology | 00000 0000000000 00.0 |
| Alector | 25-Jul-2018 | Later Stage VC | 00000 | Drug Discovery |
Merck & Co. Exits (16)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 0000000 | 25-Jul-2018 | 00000 00000 00 | 00000 | Completed |
|
| 0000000 | 07-Jan-2016 | 00000 00000 00 | 000.00 | Completed |
|
| 0000000 00000000 | 06-Jan-2016 | 000000000 | 0000 | Completed |
|
| 0000000 0000000000 | 09-Sep-2014 | 000000000000000000 | Completed |
|
|
| AdvanDx | 08-Apr-2014 | Later Stage VC | 000.00 | Completed |
|
Merck & Co. Subsidiaries (17)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Tilos Therapeutics | Biotechnology | Lexington, MA | 2016 |
| 00000000 | Biotechnology | Munich, Germany | 0000 |
| 00000 000000 00000 | Corporate Venture Capital | Kenilworth, NJ | 0000 |
| 00000 000000 | Other Pharmaceuticals and Biotechnology | Edinburgh, United Kingdom | 0000 |
| 0000000000 | Biotechnology | Australia | 0000 |
Merck & Co. Executive Team (67)
39 Former Executives
You’re viewing 5 of 67 executives. Get the full list »Merck & Co. Board Members (20)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| 0000 000000 | Self | Board Member | 000 0000 | |
| 0000000 0000000 00 | Merck & Co. | Chief Executive Officer & Chairman | 000 0000 | |
| 000000 0000 | Self | Board Member | 000 0000 | |
| 0000 000 | Merck & Co. | Board Member | 000 0000 | |
| 000000 00000 | Self | Board Member | 000 0000 |
7 Former Board Members
You’re viewing 5 of 20 board members. Get the full list »